Clozapine induced Neutropenia

Clozapine-induced neutropenia The exact mechanism is not completely established, but the best-supported model is Bioactivation of clozapine → reactive nitrenium ion → neutrophil/granulocyte precursor injury + immune-mediated destruction. 💢 Clozapine is converted to a reactive metabolite Clozapine can undergo oxidative bioactivation in neutrophils and their precursors, particularly through the myeloperoxidase (MPO)-H₂O₂-Cl⁻ system. Activated neutrophils generate hypochlorous acid (HOCl) via MPO, which can oxidize clozapine to a highly reactive nitrenium ion. 💢 Nitrenium ion damages neutrophils The nitrenium ion is highly reactive and can covalently bind to cellular proteins. This can cause: * Glutathione (GSH) depletion * oxidative/cellular stress * mitochondrial dysfunction * disruption of essential proteins * apoptosis of neutrophils Experimental studies show that therapeutic concentrations of clozapine become cytotoxic to neutrophils particularly after bioactivation to the nitrenium ion. 💢 Bone marrow granulocyte precursors are also affected This is important for understanding why the neutropenia can be profound. The target isn't only the mature circulating neutrophil. Myeloid/granulocytic precursor cells in the bone marrow can also be affected, resulting in reduced WBC production. So, here occurs ↓ production + ↑ peripheral destruction → severe neutropenia/agranulocytosis 💢 The immune mechanism: The nitrenium ion can modify neutrophil proteins and create drug-modified proteins/neo-antigens. These may be recognized by the immune system, particularly in genetically susceptible individuals. Clozapine ↓ Nitrenium ion ↓ Protein modification ↓ Neo-antigen formation ↓ Antigen presentation in susceptible HLA background ↓ Adaptive immune response ↓ Destruction of granulocytes and granulocyte precursors ↓ Neutropenia / agranulocytosis This helps explain why HLA/genetic susceptibility appears to contribute to risk. 💢 Why does it occur in only a small proportion of patients? This is an idiosyncratic adverse drug reaction, rather than a simple dose-dependent toxicity. Possible contributors include: * HLA genetic variants * differences in clozapine metabolism/bioactivation * variation in MPO/oxidative pathways * differences in apoptosis susceptibility * immune-response differences Therefore, simply increasing the dose does not reliably predict who will develop agranulocytosis. Dr. Muhammad Mosleh Uddin FCPS trainee (Cardiology) MBBS (CMC) Chittagong Medical College & Hospital